Gynecologic Cancers Research Program

妇科癌症-摘要 斯蒂芬森癌症中心（SCC）的妇科癌症（GC）计划的目标是提高 治疗标准，改善所有妇科恶性肿瘤患者的临床结局， 强调解决与SCC集水区俄克拉荷马州相关的问题。计划会员 通过进行跨学科的、以团队为基础的研究来实现这一目标， 早期和晚期随机试验的分子机制。GC计划的具体目标 主要任务是：（1）发现和研究致癌的分子机制;（2）研究 癌症治疗反应和耐药性的潜在机制;以及（3）设计和实施早期和 晚期随机临床试验，推进新的发现，并改善患者的结果， 集水区和国家。 GC计划的亮点包括：1）高度互动的基础发现和临床成员专注于 妇科癌症; 2）将这些计划成员组织成专注的翻译团队的具体目标， 导致多个PI补助金和项目内出版物的异常率; 3）妇科 肿瘤学临床计划，通过提供多学科护理和获得 俄克拉荷马州一半新GC病例的临床试验（58%的入组率）; 4）大型注释生物标本 支持GC发现研究的银行; 5）积极开展以GC为重点的药物启动试验 早期新型治疗试验中GC患者的高累积率;以及6）设计中的国家领导力 以及进行改变实践的NCTN和行业申办的随机GC试验。 GC计划有18名成员，代表七个部门，四个学院和两个机构， 说明了项目成员之间的跨学科专业知识。该计划的翻译重点是 反映在MD（9）和PhD（9）成员的平衡中。截至2016年12月31日，计划成员为 每年获得3，865，290美元的NCI和其他同行评审的癌症相关支持（直接成本）。NCI资助 （3，181，558美元）占同行评审资金的82.3%，突出了该计划的癌症重点。总 每年的GC计划资金为8，700，601美元（直接成本）。在五年报告期（2012 - 2016年），大会 项目成员发表了262篇同行评议的文章，其中34.4%包括项目内，11.8% 其中73.3%包括跨计划合作者，73.3%包括机构间合作者。2016年，方案间 出版物为21.1%，突出了与临床前研究中心正在进行的合作数量的增加 转化癌症研究（PTCR）和癌症预防和控制（CPC）计划。

GYNECOLOGIC CANCERS PROGRAM – ABSTRACT The goal of the Gynecologic Cancers (GC) program at the Stephenson Cancer Center (SCC) is to raise the standard of care and improve clinical outcomes for all women with gynecologic malignancies, with an emphasis on addressing problems relevant to Oklahoma, the SCC catchment area. Program members accomplish this goal by conducting transdisciplinary, team-based research that advances discovery of molecular mechanisms into early- and late-phase randomized trials. The Specific Aims for the GC program are: (1) to discover and interrogate molecular mechanisms central to carcinogenesis; (2) to investigate mechanisms underlying cancer therapy response and resistance; and (3) to design and conduct early- and late-phase randomized clinical trials that advance novel discoveries and improve patient outcomes in the catchment area and nation. Highlights of the GC program include: 1) highly interactive basic discovery and clinical members focused on gynecologic cancers; 2) Specific Aims that organize these program members into focused translational teams, leading to multi-PI grants and an exceptional rate of intra-programmatic publications; 3) a gynecologic oncology clinical program that impacts the catchment area by providing multidisciplinary care and access to clinical trials (58% enrollment rate) for half the new GC cases in Oklahoma; 4) a large annotated biospecimen bank that supports GC discovery research; 5) active development of GC-focused investigator-initiated trials and high accrual of GC patients to early-phase novel treatment trials; and 6) national leadership in the design and conduct of practice-changing NCTN- and Industry-sponsored randomized GC trials. The GC program has 18 members, representing seven departments, four colleges and two institutions, which illustrates the transdisciplinary expertise among program members. The translational focus of the program is reflected in the balance of MD (9) and PhD (9) members. As of December 31, 2016, program members were awarded $3,865,290 in annual NCI and other peer-reviewed cancer-related support (direct cost). NCI funding ($3,181,558) accounts for 82.3% of the peer-reviewed funding, highlighting the program's cancer focus. Total annual GC program funding is $8,700,601 (direct cost). For the five-year reporting period (2012-2016), GC program members published 262 peer-reviewed articles, of which 34.4% included intra-programmatic, 11.8% included inter-programmatic, and 73.3% included inter-institutional collaborators. For 2016, inter-programmatic publications were 21.1%, highlighting the increasing number of collaborations underway with the Preclinical Translational Cancer Research (PTCR) and Cancer Prevention and Control (CPC) programs.